ライフサイエンスコーパス: hyperthermic

1 aging and MR-guided interventions, including hyperthermic ablation of solid cancers.

2 er, they are hypermetabolic, hyperphagic and hyperthermic, all consistent with a brown phenotype.

3 ow appears to be an early defect in both the hyperthermic and adolescent paradigms.

4 increased temperatures, cocaine induced both hyperthermic and hypothermic responses.

5 re was no significant difference between the hyperthermic and normothermic tissue; there was a large

6 mothermic animals and to a greater degree in hyperthermic animals, extracellular potassium ion activi

7 Animals remained hyperthermic at 1 and 2 months p.i. and returned to prei

8 brain regions in controls and weanlings made hyperthermic by a warm environment.

9 We hypothesized that hyperthermic challenge would produce exaggerated oxidati

10 n combined with intraoperative intracavitary hyperthermic chemotherapy and trials are well under way

11 implications of intraoperative intracavitary hyperthermic chemotherapy in combination with extrapleur

12 n combined with intraoperative intracavitary hyperthermic chemotherapy.

13 umonectomy with intraoperative intracavitary hyperthermic chemotherapy.

14 umonectomy plus intraoperative intracavitary hyperthermic chemotherapy.

15 to 250 mg/m2; n = 35; median, 18 months) of hyperthermic cisplatin (P = .0019); recurrence-free inte

16 Hyperthermic cisplatin and MMC enhanced cytotoxicity whi

17 y and high-dose intraoperative intracavitary hyperthermic cisplatin lavage is feasible in this patien

18 In addition, hyperthermic combined treatment with chemotherapy and DD

19 lthough they are clearly correlated with the hyperthermic condition, the precise cellular mechanisms

20 Last, we showed that mild, fever-like hyperthermic conditions enhance the vaccine efficiency o

21 MRgHIFU was employed to create hyperthermic conditions that enhance macromolecular deli

22 tial for targeted therapies under normo- and hyperthermic conditions.

23 d hours) were normal in all normothermic and hyperthermic control rats, and none of these animals dev

24 Conversely, a minority of normothermic and hyperthermic controls had (brief) seizures, none develop

25 mia but in whom seizures had been prevented (hyperthermic controls), as well as with normothermic con

26 a uniform and mild heating profile to cause hyperthermic destruction of vessel-encasing tumors while

27 eurodegeneration in rats that did not become hyperthermic during AMPH exposure was quantified by coun

28 ed ethanol's initial hypothermic and delayed hyperthermic effect across age by 48-hr temperature meas

29 We found that the hyperthermic effect has the highest sensitivity to the e

30 aches to eliminate or minimize the on-target hyperthermic effect observed with this and other TRPV1 a

31 ed (by using knock-out mice) that the entire hyperthermic effect of AMG0347 is TRPV1 dependent.

32 ncompetitive NMDA antagonist, attenuated the hyperthermic effect of morphine (4 mg/kg).

33 acological evidence that agmatine blocks the hyperthermic effect of morphine by activating imidazolin

34 imals, centrally injected alpha-MSH exerts a hyperthermic effect that is mediated by the MC4R, consis

35 icient mice, adiponectin had only diminished hyperthermic effects but reduced RER similarly to wild t

36 bservations illustrating the augmentation of hyperthermic effects by hydralazine.

37 stigated whether NMDA receptors modulate the hyperthermic effects of acute morphine in male Sprague-D

38 The hyperthermic effects of insulin were blocked by pretreat

39 vidual variability and relatively weak brain hyperthermic effects of MDMA under standard control cond

40 In contrast, MDPV-induced hyperthermic effects were observed in only the warm ambi

41 tic nanocrystals have the ability to exhibit hyperthermic effects when placed in an oscillating magne

42 Although the combined effect of the hyperthermic events was not additive, METH administratio

43 wo natural models of ovine IUGR are those of hyperthermic exposure during pregnancy, and adolescent o

44 yperthermic slow resolvers (n = 1,452, 25%), hyperthermic fast resolvers (1,469, 25%), normothermics

45 thermic slow resolvers (n = 248 [21.8%]) and hyperthermic fast resolvers (n = 240 [18.3%]) than among

46 y n = 138 [8.6%]) had higher mortality than "hyperthermic fast resolvers" (n = 1,314 [17.0%], mortali

47 atio, 1.58; 95% CI, 1.13-2.19) compared with hyperthermic fast resolvers.

48 The hyperthermic, fast resolvers had the lowest mortality ra

49 olvers" (n = 19 cohort 1; n = 13 cohort 2), "hyperthermic, fast resolvers" (n = 18 C1; n = 24 C2), "n

50 esolvers" (n = 1,855; 14.9% of the cohort); "hyperthermic, fast resolvers" (n = 2,877; 23.2%); "normo

51 Both "hyperthermic, slow resolvers" and "hyperthermic, fast resolvers" had high levels of G-CSF,

52 to the "hyperthermic, slow resolvers," the "hyperthermic, fast resolvers" showed significant decreas

53 by coupling thermoresponsive membranes with hyperthermic Fe(3)O(4) nanoparticles and embedding them

54 The aim of this study is to evaluate mild hyperthermic heat cycling (HC) as an alternative to cont

55 adiofrequency (RF) system that enables focal hyperthermic heating, targeting, and visualization for t

56 ars; 50 women, 41 men) underwent a 90-minute hyperthermic ILP (melphalan, 10 to 13 mg/L limb volume,

57 ve stress plays a unique role in age-related hyperthermic injury and suggest that therapeutic strateg

58 herapy relative to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) al

59 Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) achiev

60 (FTR) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) across

61 Hyperthermic intraperitoneal chemotherapy (HIPEC) and cy

62 Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are be

63 Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are st

64 rvival after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) consol

65 Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for pe

66 REVIEW: Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has be

67 garding the clinical benefit of prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) in the

68 Hyperthermic intraperitoneal chemotherapy (HIPEC) is a s

69 Acute kidney injury (AKI) following hyperthermic intraperitoneal chemotherapy (HIPEC) is com

70 The aim of hyperthermic intraperitoneal chemotherapy (HIPEC) is to

71 t has already been reported.Whether adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) might

72 Evaluation of different hyperthermic intraperitoneal chemotherapy (HIPEC) regime

73 yields promising results, but the impact of hyperthermic intraperitoneal chemotherapy (HIPEC) remain

74 bel phase III OVHIPEC trial, the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to int

75 rpose of this phase II study was to evaluate hyperthermic intraperitoneal chemotherapy (HIPEC) with c

76 penetration and metabolism of oxaliplatin in hyperthermic intraperitoneal chemotherapy (HIPEC)-like t

77 es complete cytoreductive surgery (CCRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).

78 echniques such as cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC).

79 ve intent by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).

80 tients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC).

81 als with expertise in CRS included in the US Hyperthermic Intraperitoneal Chemotherapy Collaborative

82 During cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for PC, HIVM w

83 itoneal metastases; however, the addition of hyperthermic intraperitoneal chemotherapy is not recomme

84 d adequate renal function treated with NACT, hyperthermic intraperitoneal chemotherapy may be offered

85 Hyperthermic intraperitoneal chemotherapy using cisplati

86 m CRC admitted for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy were selected

87 atients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy will have loca

88 long-term (overall survival) outcomes after hyperthermic intraperitoneal chemotherapy with cytoreduc

89 Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.

90 ed total pleurectomy decortication (P/D) and hyperthermic intrapleural povidone-iodine, prophylactic

91 ast, pan-necrosis was evident 24 h after the hyperthermic ischemic insult.

92 ne TNF-alpha concentrations during and after hyperthermic isolated limb perfusion with recombinant TN

93 Hyperthermic isolated limb perfusion with recombinant TN

94 To understand the underlying mechanisms of hyperthermic killing of cancer cells, we examined the cy

95 Hyperthermic light damage in rats given linseed oil for

96 t retinal damage from either intermittent or hyperthermic light exposure.

97 to intense green light using intermittent or hyperthermic light treatments.

98 By contrast, following hyperthermic MCA occlusion, moderate-to-intense immunost

99 ration, thus opening the pathway to combined hyperthermic/mechanical nanoactuators for biomedicine.

100 t in iatrogenic injury if warming results in hyperthermic overshoot.

101 ators have applied cytoreductive surgery and hyperthermic perioperative chemotherapy as the standard

102 ned whether the in vivo relationship between hyperthermic pre-conditioning and MV infection would be

103 Hyperthermic pre-conditioning given within a therapeutic

104 Nervous tissue subjected to hyperthermic pre-conditioning is resistance to numerous

105 Hyperthermic pre-conditioning, which is known to induce

106 thesis, abolished the ameliorative effect of hyperthermic pre-conditioning.

107 ynthesis does not seem to be involved in the hyperthermic process induced by 4 mg/kg of morphine.

108 his study, we investigated the mechanisms of hyperthermic radiosensitization in GSCs by a phospho-kin

109 ivity of Ku, the DNA-PK kinase activity, and hyperthermic radiosensitization in rodent cells immediat

110 increases cell killing, a phenomenon termed hyperthermic radiosensitization.

111 f the DNA-binding activity of Ku may lead to hyperthermic radiosensitization.

112 se of DNA-PK activity did not correlate with hyperthermic radiosensitization.

113 onstitutively active AKT in GSCs compromised hyperthermic radiosensitization.

114 rature hypothermia or hyperthermia, although hyperthermic rats have greater 5-HT and 5-HIAA depletion

115 An initial hyperthermic response ( approximately 1.5 degrees C) to

116 action was followed by a large and prolonged hyperthermic response (3.5-5.0 degrees C, 5-7 hr at 9 mg

117 MDMA-induced a significant hyperthermic response and reduced the serum concentratio

118 The magnitude of the hyperthermic response depended on neither T(b) nor tail-

119 emale are also known to induce a significant hyperthermic response in the rat.

120 L-NAME (50 mg/kg, s.c.) failed to alter the hyperthermic response induced by the lower dose of morph

121 n (NIRKO mice) were unable to mount the full hyperthermic response to IGF-1, suggesting that the IGF-

122 reduction in gut bacteria and an attenuated hyperthermic response to MDMA.

123 Moreover, there was no difference in the hyperthermic response to the 5-HT depleting regimen of M

124 ing halothane anesthesia (1.75%) and have no hyperthermic response, whereas 100% Hom mice of either s

125 t with MDMA at 28 and 30 degreesC produced a hyperthermic response.

126 15 mins before or after MDMA prevented this hyperthermic response.

127 We studied hyperthermic responses of rats, mice, and guinea pigs to

128 as a two-way switch for the hypothermic and hyperthermic responses that are required for survival.

129 be a primary mechanism determining the brain hyperthermic responses.

130 duce locomotor activation and brain and body hyperthermic responses.

131 seizures in adult rats that had experienced hyperthermic seizures during infancy.

132 These data indicate that hyperthermic seizures in the immature rat model of FSs d

133 In conclusion, in the immature rat model, hyperthermic seizures lead to profound, yet primarily tr

134 nvestigated the acute and chronic effects of hyperthermic seizures on neuronal integrity and survival

135 Hyperthermic seizures-but not hyperthermia alone-resulte

136 rtant in mediating this alpha-1 AR-dependent hyperthermic shift in body temperature.

137 Following hyperthermic shock, the amounts of B1 and B2 SINE RNAs t

138 omising target for nonopioid analgesics, yet hyperthermic side effects have hindered drug development

139 Hyperthermic sites were identified by microinjecting PGE

140 st rate in hypothermics (8.5%) and lowest in hyperthermic slow resolvers (5.1%).

141 nts were classified into four subphenotypes: hyperthermic slow resolvers (n = 1,452, 25%), hypertherm

142 loodstream infections were more common among hyperthermic slow resolvers (n = 248 [21.8%]) and hypert

143 Hyperthermic slow resolvers had abnormal inflammatory ma

144 Hyperthermic slow resolvers had elevated inflammatory ma

145 Adjusted for confounders, hyperthermic slow resolvers had increased adjusted odds

146 Hyperthermic slow resolvers had increased odds of mechan

147 with significant reduction in probability of hyperthermic slow resolvers membership (27% reduction; 9

148 "Hyperthermic slow resolvers" (pooled n = 1,140 [14.8%],

149 rved a drastic decrease in the prevalence of hyperthermic slow resolvers, from representing 53% of ad

150 The hyperthermic, slow resolvers were the youngest and had t

151 perature trajectory groups were identified: "hyperthermic, slow resolvers" (n = 1,855; 14.9% of the c

152 iously validated temperature subphenotypes: "hyperthermic, slow resolvers" (n = 19 cohort 1; n = 13 c

153 Both "hyperthermic, slow resolvers" and "hyperthermic, fast re

154 In contrast to the "hyperthermic, slow resolvers," the "hyperthermic, fast r

155 Hyperthermic spreading depression (HSD) in immature rat

156 with 3 mM creatine for 3 h failed to prevent hyperthermic spreading depression occurrence; and (2) in

157 hes, activated by pharmacologics or light or hyperthermic stimuli, provide several avenues for the no

158 nfectious virus was determined in the murine hyperthermic stress (HS) model of in vivo reactivation.

159 Following hyperthermic stress (HS), which induces reactivation in

160 ng HSV-1 reactivation in mice, the effect of hyperthermic stress and cyanoketone treatment on IL-6 ex

161 Hyperthermic stress applied during the first 3 days post

162 Hyperthermic stress elicited a transient rise in IL-6 mR

163 Hyperthermic stress induces reactivation of herpes simpl

164 ivation in the trigeminal ganglion following hyperthermic stress of mice.

165 However, 24 h after the application of hyperthermic stress to mice, HSV-1 antigens were detecte

166 as induced in some of the infected mice with hyperthermic stress, and the mice were killed after 1 ho

167 the peripheral nervous system, triggered by hyperthermic stress, has been well characterized with re

168 Hyperthermic stress-induced reactivation of the HSV-1 hi

169 virus in mice from each group was induced by hyperthermic stress.

170 t viral burden reactivated in vivo following hyperthermic stress.

171 eltaPst(LAT(-)) latent TG 1 hour after mouse hyperthermic stress.

172 latently infected ganglia in vivo following hyperthermic stress.

173 re not observed in ganglia following in vivo hyperthermic stress.

174 trigeminal ganglia before and at 22 h after hyperthermic-stress-induced reactivation.

175 adult naked mole-rats exposed to a simulated hyperthermic surface environment, causing systemic hypoc

176 ma) implanted in nude mice demonstrated that hyperthermic targeting of the thermally responsive ELP f

177 oV-2 infection is the onset of fever, with a hyperthermic temperature range of 38 to 41 C.

178 ubicin that has been optimized for both mild hyperthermic temperatures (39 degrees C to 40 degrees C)

179 at human body temperature (37 degrees C) and hyperthermic temperatures (41 and 44 degrees C) reveal a

180 toneal chemotherapy (IPC) at normothermic or hyperthermic temperatures, or under pressure (CRS + IPC)

181 ch find use in clinical applications such as hyperthermic therapy, can develop inaccuracies caused by

182 Tissue sections show no hyperthermic tissue injury.

183 e 36 h of age were exposed to a 41 degrees C hyperthermic treatment for 30 min.

184 ve clinical relevance for acute burn trauma, hyperthermic treatments, and distant tissue damage after

185 Furthermore, fasted MPS IIIa mice remained hyperthermic when subjected to low temperature but becam